Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Five patients with end-stage kidney disease received genetically engineered pig kidneys through an expanded access program, with three maintaining kidney function for over eight months without dialysis and two subsequently transitioning to human donor kidneys. This represents the first documented cases of xenotransplantation functioning as genuine bridge therapy, extending dialysis-free survival while preserving access to human organ transplantation.
Scribe Therapeutics has initiated human trials of STX-1150, a gene therapy designed to silence PCSK9 and reduce LDL cholesterol. Preclinical data in primates demonstrated sustained LDL reductions exceeding 50% at therapeutic doses, with potential implications for cardiovascular risk reduction in patients with familial hypercholesterolemia or statin-resistant disease.
Rapalogix Health established a dedicated research laboratory at Princeton Innovation Center to advance translational research on rapalogs, proprietary compounds designed to modulate longevity pathways in skin. The facility enables systematic investigation of mechanism of action, formulation optimization, and biomarker development for next-generation skin longevity products.
FibroBiologics received a U.S. patent for a topical wound therapy using 3D fibroblast spheroids and fibroblast-derived materials, with preclinical evidence showing accelerated healing in diabetic and non-diabetic wound models. This approach addresses chronic wounds—a significant driver of morbidity and cost—by leveraging the regenerative capacity of fibroblast-derived signaling molecules rather than the cells themselves.
Mito Health, a direct-to-consumer diagnostics platform, has administered over one million tests across seven preventive categories including genomic sequencing, microbiome analysis, advanced imaging, and liquid biopsy screening. The expansion reflects growing demand for accessible, transparent-pricing diagnostic services that operate outside traditional insurance infrastructure.
United Therapeutics' nebulized treprostinil met its primary endpoint in phase 3 trials for idiopathic pulmonary fibrosis, demonstrating a 111.8 mL absolute improvement in forced vital capacity over 52 weeks alongside reduced acute exacerbation risk. If approved, it would represent the first inhaled antifibrotic therapy for IPF, a progressive disease with limited treatment options.
Senescent cells accumulate in aging kidneys alongside localized immune cell infiltration, with macrophages clustering preferentially around senescent tubular cells. Senolytic treatment reduces senescent cell burden and overall immune infiltration, though macrophages persist near residual senescent structures, suggesting incomplete resolution of senescence-associated inflammatory niches.
Researchers and clinicians convened to establish a clinical roadmap for senescence research, identifying priorities including functional classification of senescent states, standardized biomarkers, and precision medicine frameworks. This represents the first coordinated effort to bridge cellular senescence findings into clinical practice and policy.
Alterity Therapeutics secured a US composition-of-matter patent for ATH434 extending exclusivity to 2045, protecting the exact crystalline form used in clinical trials for Multiple System Atrophy. The patent strengthens the company's negotiating position for partnerships and creates a commercial foundation for expanding development into Parkinson's disease, a substantially larger patient population.
THPharm is using AI to identify additional therapeutic applications for THP-001, a metabolic drug currently in Phase 3 trials, by analyzing how the compound affects gene expression and biological pathways. This reverse-engineering approach reduces development risk and cost by leveraging existing safety data rather than starting clinical validation from scratch.
Resolution Therapeutics and Blood Centers of America are partnering to expand access to RTX001, a regenerative macrophage therapy designed for end-stage liver disease, with pivotal U.S. trials planned for 2027. This approach addresses a growing population of 500,000+ patients with limited transplant-free survival options by enabling treatment in community settings rather than specialized centers.
Aging-related diseases now represent the dominant global health burden across all income levels and exhibit increasing returns—meaning interventions that reduce one condition simultaneously lower risk for others. This reframing shifts the epidemiological transition from a linear model to one where integrated approaches to aging mechanisms yield compounding benefits.